{"meta":{"totalResults":11,"from":0},"results":[{"aliases":[{"type":"CodeName","name":"BTP-114"},{"type":"Synonym","name":"albumin-conjugating platinum-prodrug BTP-114"},{"type":"CodeName","name":"BTP 114"},{"type":"Synonym","name":"platinum-prodrug BTP-114"},{"type":"Synonym","name":"cisplatin prodrug BTP-114"},{"type":"Synonym","name":"cisplatin/maleimide-based complex BTP-114"},{"type":"Synonym","name":"prodrug BTP 114"}],"definition":{"html":"A proprietary, albumin-binding platinum (Pt)-based complex containing a prodrug form of the platinum compound cisplatin and a maleimide moiety, with an ability to strongly and selectively bind human serum albumin (HSA), and with potential antineoplastic activity. Upon intravenous administration, the maleimide group of BTP-114 rapidly conjugates with HSA in the bloodstream; this prolongs the blood circulation, enhances the half-life, and alters the biodistribution of BTP-114, as compared to cisplatin alone. Thus, BTP-114 demonstrates enhanced extravasation to the tumor, an increased accumulation in the tumor tissue and enhanced uptake by cancer cells. The prodrug form is reduced in the hypoxic tumor cell environment, which releases the highly cytotoxic active metabolite cisplatin. Once inside the tumor cell, cisplatin binds to nucleophilic groups, such as GC-rich sites, in DNA and induces intrastrand and interstrand DNA cross-links, resulting in apoptosis and cell growth inhibition. Compared to cisplatin alone, BTP-114 has improved selectivity towards tumor tissue, thereby enhancing efficacy while reducing systemic toxicities.","text":"A proprietary, albumin-binding platinum (Pt)-based complex containing a prodrug form of the platinum compound cisplatin and a maleimide moiety, with an ability to strongly and selectively bind human serum albumin (HSA), and with potential antineoplastic activity. Upon intravenous administration, the maleimide group of BTP-114 rapidly conjugates with HSA in the bloodstream; this prolongs the blood circulation, enhances the half-life, and alters the biodistribution of BTP-114, as compared to cisplatin alone. Thus, BTP-114 demonstrates enhanced extravasation to the tumor, an increased accumulation in the tumor tissue and enhanced uptake by cancer cells. The prodrug form is reduced in the hypoxic tumor cell environment, which releases the highly cytotoxic active metabolite cisplatin. Once inside the tumor cell, cisplatin binds to nucleophilic groups, such as GC-rich sites, in DNA and induces intrastrand and interstrand DNA cross-links, resulting in apoptosis and cell growth inhibition. Compared to cisplatin alone, BTP-114 has improved selectivity towards tumor tissue, thereby enhancing efficacy while reducing systemic toxicities."},"drugInfoSummaryLink":null,"nciConceptId":"C131607","nciConceptName":"Albumin-binding Cisplatin Prodrug BTP-114","termId":786268,"name":"Albumin-binding Cisplatin Prodrug BTP-114","firstLetter":"a","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"albumin-binding-cisplatin-prodrug-btp-114"},{"aliases":[{"type":"Abbreviation","name":"CDDP"},{"type":"Synonym","name":"DDP"},{"type":"Abbreviation","name":"DDP"},{"type":"ForeignBrandName","name":"Neoplatin"},{"type":"ObsoleteName","name":"Platinol"},{"type":"LexicalVariant","name":"cis-diammine-dichloroplatinum"},{"type":"Synonym","name":"cis-platinum"},{"type":"Synonym","name":"cis-platinum II"},{"type":"LexicalVariant","name":"cisplatinum"},{"type":"ChemicalStructureName","name":"(SP-4-2)-diamminedichloroplatinum"},{"type":"ForeignBrandName","name":"Abiplatin"},{"type":"ForeignBrandName","name":"Blastolem"},{"type":"ForeignBrandName","name":"Briplatin"},{"type":"Synonym","name":"cis-diamminedichloro platinum (II)"},{"type":"Synonym","name":"cis-diamminedichloroplatinum"},{"type":"Synonym","name":"Cis-dichloroammine Platinum (II)"},{"type":"Synonym","name":"cis-platinous diamine dichloride"},{"type":"Synonym","name":"cis-platinum II diamine dichloride"},{"type":"Synonym","name":"cis-diamminedichloridoplatinum"},{"type":"Synonym","name":"Cismaplat"},{"type":"Synonym","name":"Cisplatina"},{"type":"ForeignBrandName","name":"Cisplatyl"},{"type":"ForeignBrandName","name":"Citoplatino"},{"type":"ForeignBrandName","name":"Citosin"},{"type":"Synonym","name":"Cysplatyna"},{"type":"ForeignBrandName","name":"Lederplatin"},{"type":"ForeignBrandName","name":"Metaplatin"},{"type":"Synonym","name":"Peyrone's Chloride"},{"type":"Synonym","name":"Peyrone's Salt"},{"type":"ForeignBrandName","name":"Placis"},{"type":"ObsoleteName","name":"Plastistil"},{"type":"ForeignBrandName","name":"Platamine"},{"type":"ForeignBrandName","name":"Platiblastin-S"},{"type":"ForeignBrandName","name":"Platiblastin"},{"type":"ForeignBrandName","name":"Platinex"},{"type":"ForeignBrandName","name":"Platinol- AQ"},{"type":"ForeignBrandName","name":"Platinol-AQ VHA Plus"},{"type":"ObsoleteName","name":"Platinol-AQ"},{"type":"Synonym","name":"Platinoxan"},{"type":"Synonym","name":"platinum diamminodichloride"},{"type":"ChemicalStructureName","name":"platinum, diaminedichloro-, cis- (8CI)"},{"type":"ForeignBrandName","name":"Platiran"},{"type":"ForeignBrandName","name":"Platistin"},{"type":"ForeignBrandName","name":"Platosin"},{"type":"Synonym","name":"platinum"},{"type":"CASRegistryName","name":"15663-27-1"}],"definition":{"html":"An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.","text":"An alkylating-like inorganic platinum agent (cis-diamminedichloroplatinum) with antineoplastic activity. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/cisplatin","text":"Cisplatin"},"nciConceptId":"C376","nciConceptName":"Cisplatin","termId":39515,"name":"cisplatin","firstLetter":"c","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"cisplatin"},{"aliases":[{"type":"Synonym","name":"cisplatin, liposomal"},{"type":"CodeName","name":"SPI-077"},{"type":"Synonym","name":"STEALTH cisplatin"},{"type":"Synonym","name":"STEALTH liposomal cisplatin"},{"type":"Synonym","name":"STEALTH liposomal encapsulated cisplatin"},{"type":"Synonym","name":"STEALTH liposome cisplatin"},{"type":"Synonym","name":"liposomal cisplatin"},{"type":"CodeName","name":"SPI-77"}],"definition":{"html":"A synthetic formulation in which the antineoplastic agent cisplatin is encapsulated in lipids. Cisplatin liposomal consists of small aggregates of cisplatin covered by a single lipid bilayer. Encasement in liposomes improves cisplatin's tumor bioavailability and toxicity profile. Liposomal encapsulation does not affect the pharmacological properties of cisplatin directly. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA, inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition.","text":"A synthetic formulation in which the antineoplastic agent cisplatin is encapsulated in lipids. Cisplatin liposomal consists of small aggregates of cisplatin covered by a single lipid bilayer. Encasement in liposomes improves cisplatin's tumor bioavailability and toxicity profile. Liposomal encapsulation does not affect the pharmacological properties of cisplatin directly. Cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA, inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and cell growth inhibition."},"drugInfoSummaryLink":null,"nciConceptId":"C2502","nciConceptName":"Cisplatin Liposomal","termId":43292,"name":"cisplatin liposomal","firstLetter":"c","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"cisplatin-liposomal"},{"aliases":[{"type":"CodeName","name":"HA-132"},{"type":"CodeName","name":"HA132"},{"type":"CodeName","name":"HA 132"},{"type":"Synonym","name":"cisplatin micelle HA132"}],"definition":{"html":"A micelle formulation containing the inorganic platinum agent cisplatin, with potential antineoplastic activity. Upon administration, cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and growth inhibition of tumor cells.","text":"A micelle formulation containing the inorganic platinum agent cisplatin, with potential antineoplastic activity. Upon administration, cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and growth inhibition of tumor cells."},"drugInfoSummaryLink":null,"nciConceptId":"C190122","nciConceptName":"Cisplatin Micelle Formulation HA132","termId":810542,"name":"cisplatin micelle formulation HA132","firstLetter":"c","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"cisplatin-micelle-formulation-ha132"},{"aliases":[{"type":"Synonym","name":"cisplatin nano-engineered formulation PRV211"},{"type":"Synonym","name":"cisplatin nano-engineered intraoperative formulation PRV211"},{"type":"Synonym","name":"cisplatin nanoparticles-containing intraoperative formulation PRV211"},{"type":"Synonym","name":"intraoperative cisplatin system PRV211"},{"type":"Synonym","name":"nano-engineered hydrogel PRV211"},{"type":"Synonym","name":"nano-engineered polymeric Patch PRV211"},{"type":"CodeName","name":"PRV 211"},{"type":"CodeName","name":"PRV-211"},{"type":"CodeName","name":"PRV211"}],"definition":{"html":"A nano-engineered intraoperative system containing a liquid permeation enhancer (PE) and a patch composed of nanoparticles loaded with the inorganic platinum agent cisplatin, with potential antineoplastic and immunomodulating activities. Immediately following surgical tumor resection, the cisplatin nano-engineered intraoperative system PRV211 is applied intraoperatively; the PE is brushed onto the resected tumor bed and then the cisplatin patch is applied onto the same tumor site. Upon subsequent long-lasting and controlled release from the patch and penetration into the tumor bed, cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and growth inhibition of tumor cells. Cisplatin may reach regional lymph nodes and may trigger anti-tumor immune responses. Administration of PRV211 may eliminate any remaining micro metastases or close margins that could not be fully resected while avoiding system circulation. This may prevent systemic side effect and cancer recurrence.","text":"A nano-engineered intraoperative system containing a liquid permeation enhancer (PE) and a patch composed of nanoparticles loaded with the inorganic platinum agent cisplatin, with potential antineoplastic and immunomodulating activities. Immediately following surgical tumor resection, the cisplatin nano-engineered intraoperative system PRV211 is applied intraoperatively; the PE is brushed onto the resected tumor bed and then the cisplatin patch is applied onto the same tumor site. Upon subsequent long-lasting and controlled release from the patch and penetration into the tumor bed, cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and growth inhibition of tumor cells. Cisplatin may reach regional lymph nodes and may trigger anti-tumor immune responses. Administration of PRV211 may eliminate any remaining micro metastases or close margins that could not be fully resected while avoiding system circulation. This may prevent systemic side effect and cancer recurrence."},"drugInfoSummaryLink":null,"nciConceptId":"C204213","nciConceptName":"Cisplatin Nano-engineered Intraoperative System PRV211","termId":816034,"name":"cisplatin nano-engineered intraoperative system PRV211","firstLetter":"c","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"cisplatin-nano-engineered-intraoperative-system-prv211"},{"aliases":[{"type":"CodeName","name":"PRV111"},{"type":"CodeName","name":"PRV-111"},{"type":"CodeName","name":"PRV 111"},{"type":"Synonym","name":"cisplatin transmucosal system"},{"type":"Synonym","name":"cisplatin drug-loaded patch"}],"definition":{"html":"A transmucosal patch containing cisplatin, an inorganic platinum agent, with potential antineoplastic activity. Upon mucosal application to the tumor site in the oral cavity, and upon subsequent release from the patch, cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and growth inhibition of tumor cells.","text":"A transmucosal patch containing cisplatin, an inorganic platinum agent, with potential antineoplastic activity. Upon mucosal application to the tumor site in the oral cavity, and upon subsequent release from the patch, cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and growth inhibition of tumor cells."},"drugInfoSummaryLink":null,"nciConceptId":"C156155","nciConceptName":"Cisplatin Transmucosal Patch","termId":795340,"name":"cisplatin transmucosal patch","firstLetter":"c","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"cisplatin-transmucosal-patch"},{"aliases":[{"type":"Synonym","name":"CDDP/epi gel"},{"type":"Abbreviation","name":"CEG"},{"type":"Synonym","name":"cisplatin/epinephrine gel"},{"type":"USBrandName","name":"IntraDose"},{"type":"CodeName","name":"MPI 5010"},{"type":"Synonym","name":"CDDP-e therapeutic implant"},{"type":"Synonym","name":"CDDP/epi"},{"type":"Synonym","name":"cisplatin-epinephrine"},{"type":"Synonym","name":"intradose MPI-5010"},{"type":"Synonym","name":"MP 5010 therapeutic implant"},{"type":"Synonym","name":"MP 5010 TI"}],"definition":{"html":"An injectable gel comprised of a collagen matrix containing the inorganic platinum (Pt) agent cisplatin and the sympathomimetic agent epinephrine with potential antineoplastic activity. After intratumoral injection, cisplatin forms highly reactive, positively charged, platinum complexes, which covalently bind to nucleophilic groups in DNA, preferably at the N7 position of guanine bases. This induces both intra- and inter-strand DNA cross-links. In addition, cisplatin forms DNA-Pt-protein cross-links. Cross-link formation results in both the induction of apoptosis and cell growth inhibition. Epinephrine, a potent vasoconstrictor, is added to the gel to both enhance the penetration of cisplatin into tumor tissue and reduce its dispersion into the surrounding tissues. Intratumoral injection of cisplatin-E therapeutic implant may increase local chemotherapeutic efficacy, as compared to the systemic administration of cisplatin, while reducing its systemic toxicity.","text":"An injectable gel comprised of a collagen matrix containing the inorganic platinum (Pt) agent cisplatin and the sympathomimetic agent epinephrine with potential antineoplastic activity. After intratumoral injection, cisplatin forms highly reactive, positively charged, platinum complexes, which covalently bind to nucleophilic groups in DNA, preferably at the N7 position of guanine bases. This induces both intra- and inter-strand DNA cross-links. In addition, cisplatin forms DNA-Pt-protein cross-links. Cross-link formation results in both the induction of apoptosis and cell growth inhibition. Epinephrine, a potent vasoconstrictor, is added to the gel to both enhance the penetration of cisplatin into tumor tissue and reduce its dispersion into the surrounding tissues. Intratumoral injection of cisplatin-E therapeutic implant may increase local chemotherapeutic efficacy, as compared to the systemic administration of cisplatin, while reducing its systemic toxicity."},"drugInfoSummaryLink":null,"nciConceptId":"C17879","nciConceptName":"Cisplatin-E Therapeutic Implant","termId":42697,"name":"cisplatin-E therapeutic implant","firstLetter":"c","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"cisplatin-e-therapeutic-implant"},{"aliases":[{"type":"Synonym","name":"gemcitabine/cisplatin regimen"},{"type":"Synonym","name":"cisplatin-gemcitabine"},{"type":"Synonym","name":"cisplatin-gemcitabine regimen"},{"type":"Synonym","name":"cisplatin/gemcitabine"},{"type":"Synonym","name":"GC regimen"},{"type":"Synonym","name":"GemCis"},{"type":"Synonym","name":"gemcitabine-cisplatin"},{"type":"Synonym","name":"gemcitabine/cisplatin"},{"type":"Synonym","name":"gemcitabine-cisplatin regimen"}],"definition":{"html":"A regimen consisting of cisplatin and gemcitabine that can be used in the treatment of biliary tract, bladder, cervical, kidney, occult primary, pancreatic, ovarian, fallopian tube, primary peritoneal, and vulvar cancers, peritoneal and pleural mesothelioma, non-small cell lung cancer (NSCLC), gestational trophoblastic neoplasia (GTN), cancer of the nasopharynx, and ampullary adenocarcinoma.","text":"A regimen consisting of cisplatin and gemcitabine that can be used in the treatment of biliary tract, bladder, cervical, kidney, occult primary, pancreatic, ovarian, fallopian tube, primary peritoneal, and vulvar cancers, peritoneal and pleural mesothelioma, non-small cell lung cancer (NSCLC), gestational trophoblastic neoplasia (GTN), cancer of the nasopharynx, and ampullary adenocarcinoma."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/GEMCITABINE-CISPLATIN","text":"GEMCITABINE-CISPLATIN"},"nciConceptId":"C63406","nciConceptName":"Cisplatin/Gemcitabine Regimen","termId":631940,"name":"Cisplatin/Gemcitabine Regimen","firstLetter":"c","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"cisplatin-gemcitabine-regimen"},{"aliases":[{"type":"CodeName","name":"INT230-6"},{"type":"Synonym","name":"cisplatin/vinblastine formulation with cell penetration enhancer INT230-6"},{"type":"CodeName","name":"INT 230-6"}],"definition":{"html":"A formulation composed of three agents in a fixed ratio: two chemotherapeutic agents, the platinum compound cisplatin and the vinca alkaloid vinblastine, and a proprietary amphiphilic excipient that acts as a penetration enhancer, with potential antineoplastic activity. Upon intra-tumoral (IT) injection of INT230-6, the dispersion/cell penetration enhancer excipient of INT230-6 facilitates dispersion of the two drugs throughout the tumor tissue and enables increased cellular uptake of these agents into tumor cells. Once inside the cell, cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA, which results in apoptosis and cell growth inhibition. Vinblastine kills the tumor cells through binding to tubulin and thereby inhibits microtubule formation, resulting in disruption of the mitotic spindle assembly and cell cycle arrest of tumor. In addition, the tumor cell killing leads to recruitment of dendritic cells (DCs) and induces a tumor-specific T-cell-mediated immune response that attacks both the injected tumor and distant tumor lesions. Local administration of both cisplatin and vinblastine, without the diffusion/penetration enhancer, results in to poor diffusion and a lack of cellular uptake of the agents; INT230-6 increases the intracellular concentration of cisplatin and vinblastine, thereby improving efficacy.","text":"A formulation composed of three agents in a fixed ratio: two chemotherapeutic agents, the platinum compound cisplatin and the vinca alkaloid vinblastine, and a proprietary amphiphilic excipient that acts as a penetration enhancer, with potential antineoplastic activity. Upon intra-tumoral (IT) injection of INT230-6, the dispersion/cell penetration enhancer excipient of INT230-6 facilitates dispersion of the two drugs throughout the tumor tissue and enables increased cellular uptake of these agents into tumor cells. Once inside the cell, cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA, which results in apoptosis and cell growth inhibition. Vinblastine kills the tumor cells through binding to tubulin and thereby inhibits microtubule formation, resulting in disruption of the mitotic spindle assembly and cell cycle arrest of tumor. In addition, the tumor cell killing leads to recruitment of dendritic cells (DCs) and induces a tumor-specific T-cell-mediated immune response that attacks both the injected tumor and distant tumor lesions. Local administration of both cisplatin and vinblastine, without the diffusion/penetration enhancer, results in to poor diffusion and a lack of cellular uptake of the agents; INT230-6 increases the intracellular concentration of cisplatin and vinblastine, thereby improving efficacy."},"drugInfoSummaryLink":null,"nciConceptId":"C136428","nciConceptName":"Cisplatin/Vinblastine/Cell Penetration Enhancer Formulation INT230-6","termId":789458,"name":"cisplatin/vinblastine/cell penetration enhancer formulation INT230-6","firstLetter":"c","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"cisplatin-vinblastine-cell-penetration-enhancer-formulation-int230-6"},{"aliases":[{"type":"Synonym","name":"cisplatin/cyclophosphamide/dexamethasone/doxorubicin/etoposide"},{"type":"Synonym","name":"cisplatin/cyclophosphamide/dexamethasone/doxorubicin/etoposide regimen"},{"type":"Abbreviation","name":"D-PACE"},{"type":"Synonym","name":"decadron/platinol/adriamycin/cytoxan/etoposide regimen"},{"type":"Synonym","name":"dexamethasone-cisplatin-doxorubicin-cyclophosphamide-etoposide regimen"},{"type":"Synonym","name":"dexamethasone/cisplatin/doxorubicin/cyclophosphamide/etoposide"},{"type":"Synonym","name":"dexamethasone/cisplatin/doxorubicin/cyclophosphamide/etoposide regimen"},{"type":"Abbreviation","name":"DPACE"}],"definition":{"html":"A regimen consisting of dexamethasone, cisplatin, doxorubicin, cyclophosphamide and etoposide that may be used as a salvage regimen for aggressive and/or refractory plasma cell myeloma.","text":"A regimen consisting of dexamethasone, cisplatin, doxorubicin, cyclophosphamide and etoposide that may be used as a salvage regimen for aggressive and/or refractory plasma cell myeloma."},"drugInfoSummaryLink":null,"nciConceptId":"C137680","nciConceptName":"DPACE Regimen","termId":818450,"name":"DPACE regimen","firstLetter":"d","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"dpace-regimen"},{"aliases":[{"type":"Synonym","name":"cisplatin/etoposide/bleomycin"},{"type":"Synonym","name":"pediatric PEB"},{"type":"Synonym","name":"pediatric BEP regimen"},{"type":"Abbreviation","name":"PEB"},{"type":"Synonym","name":"platinol-etoposide-bleomycin regimen"},{"type":"Synonym","name":"cisplatin-etoposide-bleomycin regimen"}],"definition":{"html":"A chemotherapy regimen consisting of bleomycin, etoposide and cisplatin used for the treatment of pediatric germ cell tumors (GCT). In the PEB regimen, the pediatric patients receive bleomycin once per cycle and do not receive weekly bleomycin during the weeks between cycles (every 21 days); in the adult BEP regimen, patients receive weekly bleomycin.","text":"A chemotherapy regimen consisting of bleomycin, etoposide and cisplatin used for the treatment of pediatric germ cell tumors (GCT). In the PEB regimen, the pediatric patients receive bleomycin once per cycle and do not receive weekly bleomycin during the weeks between cycles (every 21 days); in the adult BEP regimen, patients receive weekly bleomycin."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/PEB","text":"PEB"},"nciConceptId":"C128248","nciConceptName":"PEB Regimen","termId":782143,"name":"PEB regimen","firstLetter":"p","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"peb-regimen"}],"links":null}